FDA made a mistake in approving a questionable Alzheimer’s drug, but Medicare could act to reduce false hopes and unethical profits
At this writing three members of the FDA Advisory Committee have chosen to resign in protest over the Food and Drug Administrations decision to approve aducanumab for the treatment of mild cognitive impairment. Their decision to resign is commendable for…
